Predictive Factors Among Clinicopathological Characteristics for Sentinel Lymph Node Metastasis in T1-T2 Breast Cancer

References

• Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7(12):983–990. doi:10.1016/S1470-2045(06)70947-017138219
   PubMed Web of Science ®Google Scholar
• Krag DN, Anderson SJ, Julian TB, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised Phase III trial. Lancet Oncol. 2007;8(10):881–888. doi:10.1016/S1470-2045(07)70278-417851130
   PubMed Web of Science ®Google Scholar
• Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med. 1998;339(14):941–946. doi:10.1056/NEJM1998100133914019753708
   PubMed Web of Science ®Google Scholar
• Kuwajerwala NK, Feczko C, Dekhne N, et al. Comparison of lymphedema in patients with axillary lymph node dissections to those with sentinel lymph node biopsy followed by immediate and delayed ALND. Am J Clin Oncol. 2013;36(1):20–23. doi:10.1097/COC.0b013e31823a495622157215
   PubMed Web of Science ®Google Scholar
• Yoshihara E, Smeets A, Laenen A, et al. Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast. 2013;22(3):357–361. doi:10.1016/j.breast.2012.09.00323022046
   PubMed Web of Science ®Google Scholar
• Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer. 2005;103(3):492–500. doi:10.1002/cncr.2080915612028
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li J, Fan Y, et al. Risk factors for axillary lymph node metastases in clinical stage T1-2N0M0 breast cancer patients. Medicine (Baltimore). 2019;98(40):e17481. doi:10.1097/MD.000000000001748131577783
   PubMed Web of Science ®Google Scholar
• Ding J, Jiang L, Wu W. Predictive value of clinicopathological characteristics for sentinel lymph node metastasis in early breast cancer. Med Sci Monit. 2017;23:4102–4108. doi:10.12659/msm.90279528839123
   PubMed Web of Science ®Google Scholar
• Ji F, Xiao WK, Yang CQ, et al. Tumor location of the central and nipple portion is associated with impaired survival for women with breast cancer. Cancer Manag Res. 2019;11:2915–2925. doi:10.2147/CMAR.S18620531040717
   PubMed Web of Science ®Google Scholar
• Ansari B, Morton MJ, Adamczyk DL, et al. Distance of breast cancer from the skin and nipple impacts axillary nodal metastases. Ann Surg Oncol. 2011;18(11):3174–3180. doi:10.1245/s10434-011-1957-z21861233
   PubMed Web of Science ®Google Scholar
• La Verde N, Biagioli E, Gerardi C, et al. Role of patient and tumor characteristics in sentinel lymph node metastasis in patients with luminal early breast cancer: an observational study. Springerplus. 2016;5(1):114. doi:10.1186/s40064-016-1720-926885467
   PubMedGoogle Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60(4):207–221. doi:10.3322/caac.2007820554718
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685. doi:10.2337/dc10-066620587728
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2010 [published correction appears in diabetes care. 2010 Mar;33(3):692]. Diabetes Care. 2010;Suppl 33(Suppl Supplement_1):S11–S61. doi:10.2337/dc10-S011.
   Web of Science ®Google Scholar
• World Health Organization. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Geneva, Switzerland: World Health Organization; 2011 Available from: https://www.who.int/diabetes/publications/report-hba1c_2011.pdf. Accessed 1223, 2020.
   Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458. doi:10.1038/bmt.2012.24423208313
   PubMed Web of Science ®Google Scholar
• Suami H, Pan W-R, Taylor GI. Historical review of breast lymphatic studies. Clin Anat. 2009;22(5):531–536. doi:10.1002/ca.2081219484798
   PubMed Web of Science ®Google Scholar
• Kasuga M, Ueki K, Tajima N, et al. Report of the japan diabetes society/japanese cancer association joint committee on diabetes and cancer. Cancer Sci. 2013;104(7):965–976. doi:10.1111/cas.1220323879470
   PubMed Web of Science ®Google Scholar
• Ferroni P, Riondino S, Laudisi A, et al. Pretreatment insulin levels as a prognostic factor for breast cancer progression. Oncologist. 2016;21(9):1041–1049. doi:10.1634/theoncologist.2015-046227388232
   PubMed Web of Science ®Google Scholar
• Monzavi-Karbassi B, Gentry R, Kaur V, et al. Pre-diagnosis blood glucose and prognosis in women with breast cancer. Cancer Metab. 2016;4(1):7. doi:10.1186/s40170-016-0147-727054036
   PubMedGoogle Scholar
• Mu L, Zhu N, Zhang J, et al. Type 2 diabetes, insulin treatment and prognosis of breast cancer. Diabetes Metab Res Rev. 2017;33(1):e2823. doi:10.1002/dmrr.2823
   Web of Science ®Google Scholar
• Lee KN, Torres MA, Troeschel AN, et al. Type 2 diabetes, breast cancer specific and overall mortality: associations by metformin use and modification by race, body mass, and estrogen receptor status. PLoS One. 2020;15(5):e0232581. doi:10.1371/journal.pone.023258132369516
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–575. doi:10.1001/jama.2011.9021304082
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–926. doi:10.1001/jama.2017.1147028898379
   PubMed Web of Science ®Google Scholar
• Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled Phase 3 trial. Lancet Oncol. 2018;19(10):1385–1393. doi:10.1016/S1470-2045(18)30380-230196031
   PubMed Web of Science ®Google Scholar
• Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310. doi:10.1016/S1470-2045(14)70460-725439688
   PubMed Web of Science ®Google Scholar